Postoperative Pain: Dynastat Cutting Up The Pain Market
Despite being recognized as one of the most common types of pain, few drugs have gained a specific indication for postoperative pain. With most patients still receiving inadequate postoperative pain relief, there is a significant opportunity for manufacturers of drugs with improved side effect profiles or novel compounds, such as Pfizer�s Dynastat, to move into the postoperative pain market.
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- TABLE OF CONTENTS - page 3
- CHAPTER 1 EXECUTIVE SUMMARY - page 5
- Introduction - page 5
- Scope and coverage of the Brief - page 5
- Key findings about postoperative pain - page 5
- Postoperative pain affects up to 53 million patients in the US alone. Despite most patients receiving some form of pain management, over half of these patients still experience inadequate pain relief. Improved patient and physician education around best practice treatment strategies is key to improving treatment outcomes. - page 6
- Opioids and traditional NSAIDs are the mainstay of postoperative pain treatment. However, compounds such as Pfizer's Dynastat, which demonstrate equivalent efficacy but fewer side effects, are desperately needed. As a result, new compounds boasting novel modes of delivery will drive patient segmentation in this developing market. - page 7
- CHAPTER 2 EPIDEMIOLOGY - page 10
- Definition of disorder - page 10
- Etiology - page 10
- Prevalence - page 10
- Surgical procedure rate - page 11
- Postoperative pain rate - page 12
- Market potential - page 13
- CHAPTER 3 CLINICAL PRACTICE - page 15
- Introduction - page 15
- Assessment of postoperative pain severity - page 16
- Professional involvement - page 17
- Clinical guidelines - page 17
- CHAPTER 4 TREATMENT OF POSTOPERATIVE PAIN - page 20
- Overview - page 20
- Opioid class - page 20
- Patient controlled analgesia - page 21
- NSAID class - page 22
- Dynastat (parecoxib) - page 22
- Strategic positioning - page 23
- Dynastat (parecoxib) - page 22
- Off-label prescribing - page 24
- Vioxx (rofecoxib) - page 24
- Neurontin (gabapentin) - page 25
- CHAPTER 5 MARKET OPPORTUNITIES - page 27
- Unmet needs and strategic recommendations - page 27
- Improved side effect profile - page 27
- Limited modes of delivery - page 28
- Niche populations - page 29
- Neuropathic postoperative pain - page 29
- Pipeline products - page 30
- DepoMorphine - page 32
- E-trans fentanyl hydrochloride - page 33
- Bicifadine - page 34
- Morphine-6-glucuronide (CEE-04-410) - page 34
- LidoPAIN-SP (lidocaine surgical pain patch) - page 35
- REN-213 - page 37
- Other compounds undergoing trials - page 37
- Oxymorphone ER - page 37
- Unmet needs and strategic recommendations - page 27
- CHAPTER 6 APPENDIX - page 39
- Bibliography - page 39
- Websites - page 43
- Disclaimer - page 45
- List of Tables
- Table 1: Key studies reporting prevalence rates of postoperative pain across the seven major markets - page 12
- Table 2: Prevalence of postoperative pain across the seven major markets, 2004 - page 13
- Table 3: Key products in R&D pipeline for postoperative pain, 2004 - page 31
- List of Figures
- Figure 1: Treatment guidelines for management of postoperative pain - page 19
Other users found this report page using the following search terms: pain postoperative pain dynastat postoperative drug operative post inadequate assessment guidelines management
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.